Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
CA 2436281 A1 · Owner: Edelman, Lena · Inventors: Jacotot, Etienne; Edelman, Lena; Briand, Jean-Paul
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A chimeric polypeptide has the formula: pTox-pTarg wherein pTox is a viral , apoptotic peptide such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide us useful for targeting pTox to cells such as cancer cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 1, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.